



Growth Factors of the Peripheral Nervous System and Neurotrophin Family

Guest Editor:

Prof. Dr. José A. Vega

1. Grupo SINPOS, Departamento de Morfología y Biología Celular, Universidad de Oviedo, Avda, Julián Clavería, 6. 33006 Oviedo, Spain

2. Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Santiago, Chile

Deadline for manuscript submissions:

closed (30 April 2024)

Message from the Guest Editor

The growth factors included in the family of neurotrophins (NGF, BDNF, NT3, NT4/5 and NT6—the latter only present in fish) constitute the paradigm of bioactive molecules with neurotrophic and neurotropic activities, especially in the peripheral nervous system. Almost 75 years have passed since the first member of the family (NGF) was discovered, and more than 30 years since the discovery of the high-affinity receptors that signal its biological functions. It was originally established that NGF was related to nociceptive primary sensory neurons and peripheral sympathetic neurons, BDNF to touch mechanoreceptive primary sensory neurons, NT3 to proprioceptive primary sensory neurons and to the enteric nervous system. But it was found that the relationships of the growth factors of this family with the peripheral nervous system are much more complex. Likewise, it is of the utmost interest to compile the therapeutic potential of this family of growth factors in the treatment of peripheral neuropathies and pathologies of the peripheral nervous system due to mutations in neurotrophins or their receptors, such as insensitivity to pain with anhidrosis.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](https://twitter.com/Biomed_MDPI)